Table 2.
Study | Year |
Plasmodium species |
Comparison groups |
Study design |
Immune status |
Age | Primary platform |
---|---|---|---|---|---|---|---|
Arévalo-Herrera et al.36 | 2016 | Plasmodium vivax | asymptomatic infection and uncomplicated malaria | CHMI | naïve or semi-immune | adults | protein microarrays |
Bediako et al.37 | 2019 | Plasmodium falciparum | high and low prior malaria exposure | prospective cohort | semi-immune | children | RNA-seq transcriptomics |
Boldt et al.38 | 2019 | Plasmodium falciparum | asymptomatic infection, uncomplicated malaria, severe malarial anemia, and cerebral malaria | cross-sectional | semi-immune | children | microarray transcriptomics |
Chakraborty et al.39 | 2018 | Plasmodium falciparum and Plasmodum vivax | severe and uncomplicated malaria | cross-sectional | semi-immune | adults | microarray transcriptomics |
Chakravorty et al.40 | 2007 | Plasmodium falciparum | in vitro co-culture of human umbilical vein endothelial cells with P. falciparum infected erythrocytes and uninfected erythrocytes | in vitro culture | naïve | not applicable | microarray transcriptomics |
Chattopadhyay et al.41 | 2011 | Plasmodium falciparum | in vitro P. falciparum sporozoite infected and non-infected HepG2-A16 liver cells | in vitro culture | not applicable | not applicable | microarray transcriptomics |
Chen et al.42 | 2010 | Plasmodium vivax | uncomplicated malaria | cross-sectional | semi-immune | adults | protein microarrays |
Chen et al.43 | 2015 | Plasmodium vivax | P. vivax exposed | cross-sectional | naïve or semi-immune | adults | protein microarrays |
Colborn et al.44 | 2015 | Plasmodium falciparum | uncomplicated malaria | cross-sectional | semi-immune | children | microarray transcriptomics |
Cordy et al.45 | 2019 | Plasmodium coatneyi and Plasmodium falciparum | uncomplicated malaria and chronic Plasmodium infection | cross-sectional | semi-immune | adults | plasma metabolomics in macaques with validation in humans |
Crompton et al.46 | 2010 | Plasmodium falciparum | malaria exposed | prospective cohort | semi-immune | children and adults | protein microarrays |
Dent et al.47 | 2015 | Plasmodium falciparum | malaria exposed | prospective cohort | semi-immune | children and adults | protein microarrays |
Dobbs et al.48 | 2017 | Plasmodium falciparum | uncomplicated malaria, convalescent malaria, and asymptomatic P. falciparum infection | longitudinal analysis | semi-immune | children | microarray transcriptomics |
Doolan et al.49 | 2008 | Plasmodium falciparum | volunteers immunized with radiation-attenuated P. falciparum sporozoites and naturally exposed donors | longitudinal analysis (vaccine study) and cross-sectional (natural malaria exposure) | previously malaria-naïve or semi-immune | children and adults | protein microarrays |
Dunache et al.50 | 2015 | Plasmodium falciparum | antigen-stimulated PBMCs from volunteers in either RTS,S/AS02A and thrombospondin-related adhesive protein (TRAP) malaria vaccine trials | vaccination and CHMI | previously malaria-naïve | adults | microarray transcriptomics |
Feintuch et al. 51 | 2016 | Plasmodium falciparum | retinopathy-positive and retinopathy-negative cerebral malaria | cross-sectional | semi-immune | children | microarray transcriptomics |
Felgner et al.52 | 2013 | Plasmodium falciparum | uncomplicated malaria | CHMI and natural infection | naïve or semi-immune | adults | protein microarrays |
Franklin et al.53 | 2009 | Plasmodium falciparum | uncomplicated malaria | cross-sectional | semi-immune | adults | microarray transcriptomics |
Gardinassi et al.54 | 2018 | Plasmodium vivax | pre-symptomatic and uncomplicated malaria | CHMI | naïve or semi-immune | adults | integrated metabolomics and transcriptomics |
Grangeiro de Carvalho et al.55 | 2011 | Plasmodium falciparum | in vitro co-culture of NK cells with P. falciparum infected erythrocytes and uninfected erythrocytes | in vitro co-culture | naïve | adults | microarray transcriptomics |
Grangeiro de Carvalho et al.56 | 2011 | Plasmodium falciparum | in vitro co-culture of NK92 cells cells with P. falciparum infected erythrocytes and uninfected erythrocytes | in vitro co-culture | naïve | adults | microarray transcriptomics |
Idaghdour et al.57 | 2012 | Plasmodium falciparum | uncomplicated malaria | case-control | semi-immune | children | Integrated transcriptomics and genomics |
Kamuyu et al.58 | 2018 | Plasmodium falciparum | malaria-exposed and malaria-naïve | cross-sectional | naïve or semi-immune | adults | protein microarrays |
Kassa et al.59 | 2011 | Plasmodium falciparum | uncomplicated malaria and severe malaria | cross-sectional | semi-immune | adults | metabolomics |
Kazmin et al.60 | 2017 | Plasmodium falciparum | volunteers immunized with RTS,S (RRR) and RTS,S/AS01 following a primary immunization with adenovirus 35 (Ad35) vector expressing circumsporozoite protein (ARR) | vaccination and CHMI | naïve | adults | microarray transcriptomics |
Keller et al.61 | 2009 | Plasmodium falciparum | in vitro culture of PBMCs from malaria-exposed and malaria-naïve donors with and without P. falciparum hemozoin | in vitro co-culture | naïve or semi-immune | children and adults | microarray transcriptomics |
Krupka et al.62 | 2012 | Plasmodium falciparum | uncomplicated malaria and severe malaria | longitudinal analysis | semi-immune | children | microarray transcriptomics |
Kumar et al.63 | 2018 | Plasmodium falciparum | cerebral malaria | case-control | semi-immune | children and adults | proteomics of frontal lobe samples |
Lee et al.64 | 2018 | Plasmodium falciparum | uncomplicated malaria and severe malaria | cross-sectional | semi-immune | children | whole-blood RNA-seq transcriptomics |
Leopold et al.65 | 2019 | Plasmodium falciparum | uncomplicated malaria and severe malaria | nested case-control | semi-immune | adults | plasma metabolomics with in vitro validation |
Lu et al.66 | 2014 | Plasmodium vivax | uncomplicated malaria | cross-sectional | naïve or semi-immune | adults | protein microarrays |
Nallandhighal et al.67 | 2019 | Plasmodium falciparum | cerebral malaria, severe malarial anemia, malaria exposed community controls | nested case-control | semi-immune | children | microarray transcriptomics with plasma biomarkers |
Nnedu et al.68 | 2011 | Plasmodium falciparum | malaria exposed with HIV co-infection | cross-sectional | semi-immune | adults | protein microarrays |
Ockenhouse et al.69 | 2006 | Plasmodium falciparum | pre-symptomatic infection and uncomplicated malaria | CHMI and natural infection | naïve or semi-immune | adults | microarray transcriptomics |
Orikiiriza et al.70 | 2017 | Plasmodium falciparum | uncomplicated malaria and severe malaria | cross-sectional | semi-immune | children | lipidomics |
Portugal et al.71 | 2014 | Plasmodium falciparum | in vitro co-culture of PBMCs with P. falciparum infected erythrocytes and uninfected erythrocytes | longitudinal analysis | semi-immune | children | microarray transcriptomics |
Quin et al.72 | 2017 | Plasmodium falciparum | malaria exposed | cross-sectional | semi-immune | adults | RNA-seq transcriptomics and genome-wide DNA methylation |
Ray et al.73 | 2012 | Plasmodium falciparum and Plasmodium vivax | uncomplicated malaria | cross-sectional | semi-immune | adults | proteomics |
Ray et al.74 | 2012 | Plasmodium vivax | uncomplicated malaria | cross-sectional | naïve or semi-immune | adults | proteomics |
Ray et al.75 | 2015 | Plasmodium falciparum | uncomplicated malaria and severe malaria | cross-sectional | semi-immune | adults | proteomics |
Reuterswärd et al.76 | 2018 | Plasmodium falciparum | uncomplicated malaria and severe malaria | case-control | semi-immune | children | proteomics |
Rojas-Peña et al.77 | 2015 | Plasmodium vivax | uncomplicated malaria | case-control | naïve or semi-immune | adults | quantitative RT-PCR array and RNA-seq transcriptomics |
Rojas-Peña et al.78 | 2018 | Plasmodium falciparum and Plasmodum vivax | malaria exposed | longitudinal analysis | semi-immune | adults | RNA-seq transcriptomics |
Rothen et al.79 | 2018 | Plasmodium falciparum | pre-symptomatic infection and uncomplicated malaria | CHMI | semi-immune | adults | RNA-seq transcriptomics |
Torres et al.80 | 2015 | Plasmodium falciparum | uncomplicated malaria and asymptomatic infection | cross-sectional | naïve or semi-immune | adults | protein microarrays |
Tran et al.81 | 2016 | Plasmodium falciparum | uncomplicated malaria and asymptomatic infection | CHMI and natural infection | naïve or semi-immune | adults | RNA-seq transcriptomics |
Tran et al.82 | 2019 | Plasmodium falciparum | volunteers immunized with sporozoites under chemoprophylaxis (CPS) | vaccination and CHMI | naïve | adults | RNA-seq transcriptomics |
Tran et al.83 | 2019 | Plasmodium falciparum | asymptomatic infection and uncomplicated malaria | nested case-control in a prospective study | semi-immune | children | RNA-seq transcriptomics |
Tripathi et al.84 | 2009 | Plasmodium falciparum | in vitro co-culture of human brain microvascular endothelial cells with P. falciparum infected erythrocytes and uninfected erythrocytes | in vitro co-culture | naïve | not applicable | microarray transcriptomics |
Uplekar et al.85 | 2017 | Plasmodium falciparum and Plasmodum vivax | asymptomatic infection, uncomplicated malaria | cross-sectional | semi-immune | adults | protein microarrays |
Vahey et al.86 | 2010 | Plasmodium falciparum | volunteers immunized with the RTS,S malaria vaccine | vaccination and CHMI | previously malaria-naïve | adults | microarray transcriptomics |
Vallejo et al.87 | 2018 | Plasmodium vivax | pre-symptomatic and uncomplicated malaria | CHMI | naïve or semi-immune | adults | RNA-seq transcriptomics |
van den Berg et al.88 | 2017 | Plasmodium falciparum | volunteers immunized with the RTS,S malaria vaccine | vaccination and CHMI | naïve | adults | microarray transcriptomics |
Yamagishi et al.89 | 2014 | Plasmodium falciparum | uncomplicated malaria | cross-sectional | semi-immune | children and adults | RNA-seq transcriptomics |